Diaries Mean – (95% CI) Escitalopram: -0.53 (-0.64 to -0.40) Placebo: -0.3 to -0.17) p<0.001* Authors’ conclusion: Authors’ conclusion: 8-week reduction in vasomotor symptom frequency from baseline relative to placebo was similar “The for escitalopram at -1.4 per day; vasomotor symptom bother reduction was minimal.” Cohen et al (2014)24, non-pharmacologic interventions (omega-3) MsFLASH 02 - Menopausal Omega-3 (1.8 Placebo Vasomotor VMS frequency at (1) Yes** Efficacy of including: grams daily for 12 symptoms 12 weeks, mean (2) Yes** Omega-3 weeks) frequency and (95% CI) (3) Yes** with a uterus Treatment for bother (4) Yes** who have skipped Vasomotor (5) Yes** 2 or more Symptoms: A Omega-3: EB risk of bias: −2.5, menstrual cycles Randomized (−3.0, Low −1.9) with an Controlled Trial: Placebo: −2.7, amenorrhea Omega-3 (−3.3, −2.2) interval days in ≥60 treatment for Relative difference the past 12 vasomotor of 0.3 hot months. symptoms flashes per day who have had (95% CI 1.0, −0.5, a bi-lateral N = 295 p=0.28) oophorectomy Age = 40-62 years (surgical removal Duration = 12 VMS bother at 12 of both ovaries). weeks weeks, mean (95% Follow-up = at 8 or CI) Women without a 12 weeks uterus who still (−0.6, −0.5 have ovaries, −0.4) under certain conditions
Diaries – Mean (95% CI) Escitalopram: -0.53 (-0.64 to -0.40) Placebo: -0.3 to -0.17) p<0.001* Authors’ conclusion: Authors’ conclusion: “The 8-week reduction in vasomotor symptom frequency from baseline relative to placebo was similar for escitalopram at -1.4 per day; vasomotor symptom bother reduction was minimal.” Cohen et al (2014)24, non-pharmacologic interventions (omega-3) MsFLASH 02 - Efficacy of Omega-3 Treatment for Vasomotor Symptoms: A Randomized Controlled Trial: Omega-3 treatment for vasomotor symptoms N = 295 Age = 40-62 years Duration = 12 weeks Follow-up = at 8 or 12 weeks Menopausal including: with a uterus who have skipped 2 or more menstrual cycles with an amenorrhea interval ≥60 days in the past 12 months. who have had a bi-lateral oophorectomy (surgical removal of both ovaries). Women without a uterus who still have ovaries, under certain conditions Omega-3 (1.8 grams daily for 12 weeks) Placebo Vasomotor symptoms frequency and bother VMS frequency at 12 weeks, mean (95% CI) Omega-3: −2.5, (−3.0, −1.9) Placebo: −2.7, (−3.3, −2.2) Relative difference of 0.3 hot flashes per day (95% CI −0.5, 1.0, p=0.28) VMS bother at 12 weeks, mean (95% CI) −0.5 (−0.6, −0.4) (1) Yes** (2) Yes** (3) Yes** (4) Yes** (5) Yes** EB risk of bias: Low